Type 2 & other diabetes

Diabetes mellitus with mild or moderate kidney dysfunction is associated with poor prognosis in patients with coronary artery disease: A large-scale cohort study

Diabetes Res Clin PractPublished Prospective cohort study

Authors' conclusion

DM with mild or moderate kidney dysfunction is associated with poor prognosis in CAD patients. Categorical classification of patients with DM and kidney dysfunction could provide prognostic information for risk stratification of CAD patients.

Study context

Population
Patients with coronary artery disease (CAD) hospitalized for percutaneous coronary intervention (PCI) at Fuwai hospital, January–December 2013
Participants
9,293 patients
Exposure
Combined DM status and kidney function stage vs stage I/non-DM
Outcome
MACCEs: composite of all-cause mortality, MI and stroke
Follow-up
Median 2.4 years
Methodological detailssingle-centre
  • Single-centre

Main finding

As reported in the abstract

MACCE risk
Each group vs stage I/non-DMAdjusted hazard ratio (95% CI)P value
Stage II/DM
1.53(1.09–2.15)
P = 0.014
Stage III/DM
3.00(1.74–5.18)
P < 0.002
Major adverse cardiovascular and cerebrovascular events (MACCEs) occurred (all patients)
326 (3.5%)

Observational data: associations, not effects.

Further findings

Estimated glomerular filtration rate (eGFR) and MACCE risk

J-shaped associations of eGFR with MACCE risk regardless of glycemic metabolism status, after adjustment for confounders

MACCE risk with moderate kidney dysfunction in diabetic patients with uncontrolled glycemia

Moderate kidney dysfunction conferred increased MACCE risk, aHR
2.93 (95% CI 1.48-5.78; P = 0.002)

Original publication

Diabetes mellitus with mild or moderate kidney dysfunction is associated with poor prognosis in patients with coronary artery disease: A large-scale cohort study. Diabetes Res Clin Pract. Published 7 May 2023. doi:10.1016/j.diabres.2023.110693

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.